Rapidly identify agents that modulate T cells, in high throughput leveraging Horizon’s extensive experience in compound screening. We will provide analysis of the effects of your biologics or small molecules from multiple donors.
|Service description||Number of suitable compounds||Catalog number|
|Standard T-cell activation assay - Mini||1 to 3||IMM03-01|
|Standard T-cell activation assay - Midi||4 to 9||IMM03-02|
|Standard T-cell activation assay - Maxi||10 to 15||IMM03-03|
Standard T cell activation readouts and cloud-based data report
- T cell viability
- Percentage of proliferation of CD4+
- Percentage of proliferation of CD8+
- Percentage of proliferation of CD25+CD4+ and CD25+CD8+
- 9 points dose response. (8 dilutions + vehicle)
- Data points set of quadruplicates
- 3-fold dilution range
- All plotted data and raw data files are provided
Representative flow cytometry plots of T Cell Activation Assay
A) Percentage of activated CD8+ T cells after treatment with PCI 29732, as measured by CD25 expression. Three donors depicted. B) Percentage of proliferating CD4+ T cells after treatment with anti-CD28 antibody, measured by CellTrace Violet (CTV) staining. Single donor shown. Plot includes IgG1 isotype control. C) Percentage of activated CD8+ T cells after treatment with Daclizumab, as measured by CD25 expression. Plot includes IgG1 isotype control. Single donor shown.
Contact us to discuss your project using the form provided and one of the team will be in touch within 48 hours
Answer questions in biologically relevant primary immune cell types. Leveraging our expertise in screening and receive robust data from high-throughput assays.
Read Horizon's immunology blog
Get the latest insights about the drug discovery tools in the immunology field, curated by Horizon's scientists.